Pancreatic Cancer Research

ResearcherChinese Academy of Medical Sciences & Peking Union Medical CollegeActive in the last 2 years

Menghua Dai

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-7273-6282; OpenAlex author ID A5031450490. Sources: ClinicalTrials.gov.

Their work

Papers
46 (first author 1, last author 9)
Trials
2 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
124
Papers, trials and grants by year

2013: 2 papers · 2014: none · 2015: none · 2016: none · 2017: none · 2018: 2 papers · 2019: 4 papers · 2020: 8 papers, 2 trials · 2021: 7 papers · 2022: 5 papers · 2023: 3 papers · 2024: 6 papers · 2025: 5 papers · 2026: 4 papers

Papers 46

  1. Tumor-Derived LAMB3 Drives Immunosuppressive LRRC15+ Fibroblast Formation During Pancreatic Ductal Adenocarcinoma Development. Co-author DOI 10.1002/advs.202520029↗
  2. Identifying a better-prognosis pancreatic cancer from its benign inflammatory mimic: a machine learning approach with contrast-enhanced ultrasound for early in… Co-author DOI 10.1007/s00261-026-05423-2↗
  3. Multifrequency magnetic resonance elastography for predicting pancreatic cancer aggressiveness and patient survival. Co-author DOI 10.1007/s00330-026-12824-w↗
  4. A conserved re-epithelialization program underlies malignancy in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ccell.2026.03.021↗
  5. Development and validation of a nomogram model based on ultrasound and contrast-enhanced ultrasound features for differentiating mass-forming pancreatitis and … Co-author DOI 10.1007/s00261-025-05035-2↗
  6. Oral and fecal microbiota as accurate non-invasive tools for detection of pancreatic cancer in the Chinese population. Last author DOI 10.1016/j.canlet.2025.217456↗
  7. MRI-derived extracellular volume fraction as a prognostic biomarker for early recurrence after R0 resection of pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.ejro.2025.100711↗
  8. Erratum: Chinese expert consensus on imaging assessment of pancreatic ductal adenocarcinoma (PDAC) resectability. Co-author DOI 10.1097/jp9.0000000000000235↗
  9. Integrative metagenomic and metabolomic profiling identifies gut microbial and metabolite signatures associated with lymph node metastasis in pancreatic cancer. Last author DOI 10.3389/fmicb.2025.1706084↗
  10. Current status and prospect of gut and oral microbiome in pancreatic cancer: Clinical and translational perspectives. Last author DOI 10.1016/j.canlet.2024.217274↗
  11. Difference in fecal and oral microbiota between pancreatic cancer and benign/low-grade malignant tumor patients. Last author DOI 10.1186/s12866-024-03687-6↗
  12. Efficacy of color Doppler ultrasound and contrast-enhanced ultrasound in identifying vascular invasion in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13244-024-01779-5↗
  13. Development and validation of a nomogram model based on pretreatment ultrasound and contrast-enhanced ultrasound to predict the efficacy of neoadjuvant chemoth… Co-author DOI 10.1186/s40644-024-00662-2↗
  14. Robotic Versus Laparoscopic Pancreaticoduodenectomy for Pancreatic Cancer: Evaluation and Analysis of Surgical Efficacy. Co-author DOI 10.1245/s10434-024-15764-1↗
  15. ASO Author Reflections: The Advantages of Robotic Pancreaticoduodenectomy for Pancreatic Cancer. First author DOI 10.1245/s10434-024-15871-z↗
  16. Pancreatic stellate cells exploit Wnt/β-catenin/TCF7-mediated glutamine metabolism to promote pancreatic cancer cells growth. Co-author DOI 10.1016/j.canlet.2022.216040↗
  17. Pancreatic ductal adenocarcinoma with synchronous and metachronous hepatic metastasis predicted by contrast-enhanced ultrasound. Co-author DOI 10.21037/qims-22-1132↗
  18. Collagen type VII α1 chain: A promising prognostic and immune infiltration biomarker of pancreatic cancer. Co-author DOI 10.3892/ol.2023.13663↗
  19. Multi-omics analysis of intra-tumoural and inter-tumoural heterogeneity in pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ctm2.670↗
  20. Comparison of adjuvant gemcitabine plus S-1 with S-1 monotherapy for pancreatic ductal adenocarcinoma: Retrospective real-world data. Co-author DOI 10.1016/j.neo.2022.100841↗
  21. Construction and Validation of a Necroptosis-Related Gene Signature for Predicting Prognosis and Tumor Microenvironment of Pancreatic Cancer. Co-author DOI 10.1155/2022/9737587↗
  22. Noninvasive detection of pancreatic ductal adenocarcinoma using the methylation signature of circulating tumour DNA. Co-author DOI 10.1186/s12916-022-02647-z↗
  23. The effect of minimally invasive or open radical antegrade modular pancreatosplenectomy on pancreatic cancer: A multicenter randomized clinical trial protocol. Co-author DOI 10.3389/fonc.2022.965508↗
  24. Distinguishing pancreatic cancer and autoimmune pancreatitis with in vivo tomoelastography. Co-author DOI 10.1007/s00330-020-07420-5↗
  25. Comparison of minimal invasive versus open radical antegrade modular pancreatosplenectomy (RAMPS) for pancreatic ductal adenocarcinoma: a single center retrosp… Last author DOI 10.1007/s00464-020-07938-1↗
  26. Radical antegrade modular pancreatosplenectomy (RAMPS) versus conventional distal pancreatosplenectomy (CDPS) for left-sided pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00595-020-02203-3↗
  27. Metformin inhibits pancreatic cancer metastasis caused by SMAD4 deficiency and consequent HNF4G upregulation. Co-author DOI 10.1007/s13238-020-00760-4↗
  28. ROBO2 hampers malignant biological behavior and predicts a better prognosis in pancreatic adenocarcinoma. Last author DOI 10.1080/00365521.2021.1930144↗
  29. Quantitative assessment of the diagnostic role of mucin family members in pancreatic cancer: a meta-analysis. Co-author DOI 10.21037/atm-20-5606↗
  30. Correlation Between Enhancement Patterns on Transabdominal Ultrasound and Survival for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.2147/cmar.s307079↗
  31. Combined blockade of TGf-β1 and GM-CSF improves chemotherapeutic effects for pancreatic cancer by modulating tumor microenvironment. Co-author DOI 10.1007/s00262-020-02542-7↗
  32. Prognostic and predictive value of a five-molecule panel in resected pancreatic ductal adenocarcinoma: A multicentre study. Co-author DOI 10.1016/j.ebiom.2020.102767↗
  33. Mucins in pancreatic cancer: A well-established but promising family for diagnosis, prognosis and therapy. Co-author DOI 10.1111/jcmm.15684↗
  34. Research Progress on Slit/Robo Pathway in Pancreatic Cancer: Emerging and Promising. Last author DOI 10.1155/2020/2845906↗
  35. High Expression of MUC15 Is Correlated with Poor Prognosis of Pancreatic Cancer and Promotes Migration, Invasion, and Chemo-Resistance In Vitro. Co-author DOI 10.12659/msm.926432↗
  36. Pancreatic cancer with ovarian metastases: A case report and review of the literature. Co-author DOI 10.12998/wjcc.v8.i21.5380↗
  37. Glutathione S-Transferase Mu-3 Predicts a Better Prognosis and Inhibits Malignant Behavior and Glycolysis in Pancreatic Cancer. Co-author DOI 10.3389/fonc.2020.01539↗
  38. Tumor microenvironment in chemoresistance, metastasis and immunotherapy of pancreatic cancer. Co-author PMID 32774994↗
  39. Experts' consensus on intraoperative radiotherapy for pancreatic cancer. Co-author DOI 10.1016/j.canlet.2019.01.038↗
  40. CTC phenotyping for a preoperative assessment of tumor metastasis and overall survival of pancreatic ductal adenocarcinoma patients. Co-author DOI 10.1016/j.ebiom.2019.07.044↗
  41. Single-cell RNA-seq highlights intra-tumoral heterogeneity and malignant progression in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41422-019-0195-y↗
  42. Author Correction: Single-cell RNA-seq highlights intra-tumoral heterogeneity and malignant progression in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41422-019-0212-1↗
  43. Tumor size classification of the 8th edition of TNM staging system is superior to that of the 7th edition in predicting the survival outcome of pancreatic canc… Co-author DOI 10.1038/s41598-018-28193-4↗
  44. Prognostic significance of circulating tumor microemboli in patients with pancreatic ductal adenocarcinoma. Last author DOI 10.3892/ol.2018.8264↗
  45. Diagnostic accuracy of endoscopic ultrasound-guided fine-needle aspiration for pancreatic cancer: a meta-analysis. Co-author DOI 10.1016/j.pan.2013.01.013↗
  46. [The role of perioperative enteral and parenteral nutrition treatment in pancreatic cancer: a multicenter, prospective randomized controlled trial]. Co-author PMID 24444682↗

Trials 2

  1. Using Digestive Microbial Information to Enhance the Early Detection of Pancreatic Cancer Principal investigator NCT05689138↗
  2. Fecal and Oral Microbiota Between Pancreatic Cancer and Benign/Low-grade Malignant Tumor Patients Study chair NCT06659237↗

Closest collaborators

The 25 strongest of 124 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hanyu Zhang · 8 shared papers, 2020–2025 · strength 1.58
  2. Yupei Zhao · 13 shared papers, 2013–2026 · strength 1.51
  3. Junchao Guo · 11 shared papers, 2013–2024 · strength 1.22
  4. Cheng Ding · 8 shared papers, 2020–2023 · strength 1.16
  5. Zhiyong Liang · 6 shared papers, 2020–2026 · strength 0.99
  6. Shunda Wang · 7 shared papers, 2020–2021 · strength 0.97
  7. Taiping Zhang · 10 shared papers, 2013–2022 · strength 0.94
  8. Huanwen Wu · 6 shared papers, 2020–2026 · strength 0.87
  9. Weibin Wang · 4 shared papers, 2024–2026 · strength 0.87
  10. Liang Zhu · 4 shared papers, 2020–2026 · strength 0.83
  11. Lei You · 6 shared papers, 2020–2021 · strength 0.83
  12. Pengyu Li · 3 shared papers, 2024–2025 · strength 0.81
  13. Yuejuan Cheng · 5 shared papers, 2021–2024 · strength 0.78
  14. Ke Lv · 4 shared papers, 2021–2026 · strength 0.73
  15. Lixin Chen · 2 shared papers, 2024 · strength 0.66
  16. Shuai Yuan · 3 shared papers, 2024–2025 · strength 0.66
  17. Xiaoding Liu · 4 shared papers, 2022–2026 · strength 0.64
  18. Quan Liao · 6 shared papers, 2018–2021 · strength 0.57
  19. Yuxin Jiang · 3 shared papers, 2021–2026 · strength 0.51
  20. Qiaofei Liu · 4 shared papers, 2020–2023 · strength 0.49
  21. Junchao Guo · 2 shared papers, 2025–2026 · strength 0.48
  22. Ingolf Sack · 2 shared papers, 2021–2026 · strength 0.42
  23. Yu-Pei Zhao · 3 shared papers, 2013–2021 · strength 0.38
  24. Hangqi Liu · 2 shared papers, 2023–2026 · strength 0.38
  25. Huadan Xue · 2 shared papers, 2021–2025 · strength 0.38

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.